Surgeons largely left out of ACO efforts

Although surgical procedures are among the most expensive of claims, Accountable Care Organization (ACO) cost reduction efforts don’t pay much attention to surgery as an area where possible waste in healthcare delivery may occur finds a new study published in Health Affairs.

Policy researchers from the American College of Surgeons, Harvard Medical School and the think tank Brookings Institution examined the experience of 59 Medicare-approved ACOs and found that all were largely focused on primary care changes and comparatively little if any effort had gone into projects to make specialty care, and in particular surgery, more cost effective. Surgeons also were under-represented in ACO leadership.

The researcher predicted that eventually ACOs will focus more on surgical care and use data on outcomes and costs to make referrals more scientific. This change in referral patterns will in turn create the incentive for surgeons, hospitals and surgery centers to focus on efforts to reduce waste and improve results.

However, the authors also noted that of course local market conditions could restrict ACOs’ abilities to change surgeons’ behavior through more cost and quality based referral patterns.

Lena Kauffman,

Contributor

Lena Kauffman is a contributing writer based in Ann Arbor, Michigan.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.